175 related articles for article (PubMed ID: 36010973)
1. Super Enhancer-Regulated
Piipponen M; Riihilä P; Knuutila JS; Kallajoki M; Kähäri VM; Nissinen L
Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010973
[TBL] [Abstract][Full Text] [Related]
2. C1r Upregulates Production of Matrix Metalloproteinase-13 and Promotes Invasion of Cutaneous Squamous Cell Carcinoma.
Viiklepp K; Nissinen L; Ojalill M; Riihilä P; Kallajoki M; Meri S; Heino J; Kähäri VM
J Invest Dermatol; 2022 May; 142(5):1478-1488.e9. PubMed ID: 34756877
[TBL] [Abstract][Full Text] [Related]
3. p53-Regulated Long Noncoding RNA PRECSIT Promotes Progression of Cutaneous Squamous Cell Carcinoma via STAT3 Signaling.
Piipponen M; Nissinen L; Riihilä P; Farshchian M; Kallajoki M; Peltonen J; Peltonen S; Kähäri VM
Am J Pathol; 2020 Feb; 190(2):503-517. PubMed ID: 31837949
[TBL] [Abstract][Full Text] [Related]
4. Complement factor I upregulates expression of matrix metalloproteinase-13 and -2 and promotes invasion of cutaneous squamous carcinoma cells.
Rahmati Nezhad P; Riihilä P; Piipponen M; Kallajoki M; Meri S; Nissinen L; Kähäri VM
Exp Dermatol; 2021 Nov; 30(11):1631-1641. PubMed ID: 33813765
[TBL] [Abstract][Full Text] [Related]
5. Tumor cell-specific AIM2 regulates growth and invasion of cutaneous squamous cell carcinoma.
Farshchian M; Nissinen L; Siljamäki E; Riihilä P; Piipponen M; Kivisaari A; Kallajoki M; Grénman R; Peltonen J; Peltonen S; Quint KD; Bavinck JNB; Kähäri VM
Oncotarget; 2017 Jul; 8(28):45825-45836. PubMed ID: 28526809
[TBL] [Abstract][Full Text] [Related]
6. EphB2 Promotes Progression of Cutaneous Squamous Cell Carcinoma.
Farshchian M; Nissinen L; Siljamäki E; Riihilä P; Toriseva M; Kivisaari A; Ala-Aho R; Kallajoki M; Veräjänkorva E; Honkanen HK; Heljasvaara R; Pihlajaniemi T; Grénman R; Peltonen J; Peltonen S; Kähäri VM
J Invest Dermatol; 2015 Jul; 135(7):1882-1892. PubMed ID: 25789706
[TBL] [Abstract][Full Text] [Related]
7. Long Noncoding RNA PICSAR Promotes Growth of Cutaneous Squamous Cell Carcinoma by Regulating ERK1/2 Activity.
Piipponen M; Nissinen L; Farshchian M; Riihilä P; Kivisaari A; Kallajoki M; Peltonen J; Peltonen S; Kähäri VM
J Invest Dermatol; 2016 Aug; 136(8):1701-1710. PubMed ID: 27049681
[TBL] [Abstract][Full Text] [Related]
8. New perspectives on role of tumor microenvironment in progression of cutaneous squamous cell carcinoma.
Nissinen L; Farshchian M; Riihilä P; Kähäri VM
Cell Tissue Res; 2016 Sep; 365(3):691-702. PubMed ID: 27411692
[TBL] [Abstract][Full Text] [Related]
9. Identifying an lncRNA-Related ceRNA Network to Reveal Novel Targets for a Cutaneous Squamous Cell Carcinoma.
Xu Y; Dong Y; Deng Y; Qi Q; Wu M; Liang H; She Q; Guo Q
Biology (Basel); 2021 May; 10(5):. PubMed ID: 34068010
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA31 and MMP-1 contribute to the differentiated pathway of invasion -with enhanced epithelial-to-mesenchymal transition- in squamous cell carcinoma of the skin.
Fernández-Figueras MT; Carrato C; Saenz-Sardà X; Musulén E; Fuente MJ; Puig L
Arch Dermatol Res; 2022 Oct; 314(8):767-775. PubMed ID: 34647185
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-125b down-regulates matrix metallopeptidase 13 and inhibits cutaneous squamous cell carcinoma cell proliferation, migration, and invasion.
Xu N; Zhang L; Meisgen F; Harada M; Heilborn J; Homey B; Grandér D; Ståhle M; Sonkoly E; Pivarcsi A
J Biol Chem; 2012 Aug; 287(35):29899-908. PubMed ID: 22782903
[TBL] [Abstract][Full Text] [Related]
12. Complement factor H: a biomarker for progression of cutaneous squamous cell carcinoma.
Riihilä PM; Nissinen LM; Ala-Aho R; Kallajoki M; Grénman R; Meri S; Peltonen S; Peltonen J; Kähäri VM
J Invest Dermatol; 2014 Feb; 134(2):498-506. PubMed ID: 23938460
[TBL] [Abstract][Full Text] [Related]
13. Characterization of super-enhancer-associated functional lncRNAs acting as ceRNAs in ESCC.
Wang QY; Peng L; Chen Y; Liao LD; Chen JX; Li M; Li YY; Qian FC; Zhang YX; Wang F; Li CQ; Lin DC; Xu LY; Li EM
Mol Oncol; 2020 Sep; 14(9):2203-2230. PubMed ID: 32460441
[TBL] [Abstract][Full Text] [Related]
14. Tumour-cell-derived complement components C1r and C1s promote growth of cutaneous squamous cell carcinoma.
Riihilä P; Viiklepp K; Nissinen L; Farshchian M; Kallajoki M; Kivisaari A; Meri S; Peltonen J; Peltonen S; Kähäri VM
Br J Dermatol; 2020 Mar; 182(3):658-670. PubMed ID: 31049937
[TBL] [Abstract][Full Text] [Related]
15. Complement Factor D Is a Novel Biomarker and Putative Therapeutic Target in Cutaneous Squamous Cell Carcinoma.
Rahmati Nezhad P; Riihilä P; Knuutila JS; Viiklepp K; Peltonen S; Kallajoki M; Meri S; Nissinen L; Kähäri VM
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053469
[TBL] [Abstract][Full Text] [Related]
16. Complement factor I promotes progression of cutaneous squamous cell carcinoma.
Riihilä P; Nissinen L; Farshchian M; Kivisaari A; Ala-Aho R; Kallajoki M; Grénman R; Meri S; Peltonen S; Peltonen J; Kähäri VM
J Invest Dermatol; 2015 Feb; 135(2):579-588. PubMed ID: 25184960
[TBL] [Abstract][Full Text] [Related]
17. Risk Factors and Prognosis for Metastatic Cutaneous Squamous Cell Carcinoma: A Cohort Study.
Knuutila JS; Riihilä P; Kurki S; Nissinen L; Kähäri VM
Acta Derm Venereol; 2020 Sep; 100(16):adv00266. PubMed ID: 32930344
[TBL] [Abstract][Full Text] [Related]
18. Complement Component C3 and Complement Factor B Promote Growth of Cutaneous Squamous Cell Carcinoma.
Riihilä P; Nissinen L; Farshchian M; Kallajoki M; Kivisaari A; Meri S; Grénman R; Peltonen S; Peltonen J; Pihlajaniemi T; Heljasvaara R; Kähäri VM
Am J Pathol; 2017 May; 187(5):1186-1197. PubMed ID: 28322200
[TBL] [Abstract][Full Text] [Related]
19. MMP1 regulated by NEAT1/miR-361-5p axis facilitates the proliferation and migration of cutaneous squamous cell carcinoma via the activation of Wnt pathway.
Jiang S; Liu H; Zhang J; Zhang F; Fan J; Liu Y
Cancer Biol Ther; 2021 Jun; 22(5-6):381-391. PubMed ID: 34369270
[TBL] [Abstract][Full Text] [Related]
20. Cancer Progression Gene Expression Profiling Identifies the Urokinase Plasminogen Activator Receptor as a Biomarker of Metastasis in Cutaneous Squamous Cell Carcinoma.
Minaei E; Mueller SA; Ashford B; Thind AS; Mitchell J; Perry JR; Genenger B; Clark JR; Gupta R; Ranson M
Front Oncol; 2022; 12():835929. PubMed ID: 35480116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
